Pfenex to Report First Quarter 2018 Results and Provide Business Update on Thursday, May 10th

SAN DIEGO, April 30, 2018 /PRNewswire/ -- Pfenex Inc. (NYSE American: PFNX) announced today that its first quarter 2018 financial results will be released on Thursday, May 10, 2018, after the market close. Pfenex management will host a corresponding conference call and a live webcast at 4:30 pm ET/1:30 pm PT on the same day to discuss the financial results and provide a business update.


    Thursday, May 10, 2018 @ 4:30 pm Eastern Time/1:30 pm Pacific Time

    US Toll Free:                        866-376-8058

    International:                       412-542-4131

    Access Code:                                                       10120009


    A replay of the call will be available through May 17th:

    US Toll Free:                        877-344-7529

    International:                       412-317-0088

    Replay Access Code:                                                10120009


Pfenex investors and others should note that we announce material information to the public about the Company through a variety of means, including our website (, our investor relations website (, press releases, SEC filings, public conference calls, corporate Twitter account (, Facebook page (, and LinkedIn page ( in order to achieve broad, non-exclusionary distribution of information to the public and to comply with our disclosure obligations under Regulation FD. We encourage our investors and others to monitor and review the information we make public in these locations as such information could be deemed to be material information. Please note that this list may be updated from time to time.

About Pfenex Inc.
Pfenex is a clinical-stage development and licensing biotechnology company focused on leveraging its Pfenex Expression Technology® to improve protein therapies for unmet patient needs. Using the patented Pfenex Expression Technology platform, the Company has created an advanced pipeline of therapeutic equivalents, vaccines, biologics and biosimilars. The Company's lead product candidates are PF708, a therapeutic equivalent candidate to Forteo® (teriparatide) for the treatment of osteoporosis, and its novel anthrax vaccine candidates, Px563L and RPA563, funded through an advanced development contract with the U.S. government. In addition, the Company is developing hematology/oncology products in collaboration with Jazz Pharmaceuticals. Furthermore, our pipeline includes biosimilar candidates to Lucentis® and Neulasta®.

CONTACT: Susan A. Knudson, Chief Financial Officer, (858) 352-4324,, Hans Vitzthum, Managing Director, LifeSci Advisors, LLC, (617) 535-7743,

View original content with multimedia:

SOURCE Pfenex Inc.

Back to news